Mark Elliott Boulding - 07 Oct 2025 Form 4 Insider Report for PTC THERAPEUTICS, INC. (PTCT)

Role
EXEC. VP AND CLO
Signature
/s/ Avraham S. Adler, Attorney-in-Fact
Issuer symbol
PTCT
Transactions as of
07 Oct 2025
Net transactions value
-$85,504
Form type
4
Filing time
09 Oct 2025, 17:20:05 UTC
Previous filing
07 Oct 2025
Next filing
19 Nov 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Boulding Mark Elliott EXEC. VP AND CLO C/O PTC THERAPEUTICS, INC., 500 WARREN CORPORATE CENTER DRIVE, WARREN /s/ Avraham S. Adler, Attorney-in-Fact 09 Oct 2025 0001578852

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PTCT Common Stock Options Exercise $128,588 +3,375 +3.2% $38.10 107,276 07 Oct 2025 Direct F1
transaction PTCT Common Stock Sale $110,498 -1,757 -1.6% $62.89 105,519 07 Oct 2025 Direct F1, F2
transaction PTCT Common Stock Sale $83,323 -1,306 -1.2% $63.80 104,213 07 Oct 2025 Direct F1, F3
transaction PTCT Common Stock Sale $20,271 -312 -0.3% $64.97 103,901 07 Oct 2025 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PTCT Stock Option (Right to Buy) Options Exercise $0 -3,375 -50% $0.000000 3,376 07 Oct 2025 Common Stock 3,375 $38.10 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024.
F2 This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $62.36 to $63.28 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F3 This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $63.36 to $64.25 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F4 This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $64.56 to $65.01 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F5 This option was granted on January 7, 2022, and vests over four years, with 25% of the shares underlying the option vesting on January 7, 2023, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 7, 2023.